Beyond the Hype: What GLP-1s Mean for Policy and Employers
About this episode
This episode discusses the impact of GLP-1 medications on employer benefits and health policy.
GLP-1 medications like Ozempic and Wegovy have quickly moved from niche treatments to the center of high-stakes conversations across payers about cost, access, and coverage. In this episode, Coral Partner Alison Falb talks with Laura Rudder Huff, Vice President at Gallagher Research & Insights, about how the rise of GLP-1s is shaping employer benefit strategies, equity considerations, and policy debates.
More episodes of Pop Health Podcast
- Reimagining Post-Acute Care: Why the Future of Recovery Happens at Home
- From Concept to Model: The Making of LEAD
- Primary Care Population-Based Payment and Value Based Payment State Lessons
- What the LEAD Model Means for ACOs and the Future of Value-Based Care
- New Model Mania: Unpacking CMS's RHTP, ASM, LEAD, ACCESS, and ELEVATE
- Rural Health Transformation: How States Can Align Stakeholders for Lasting Change
Explore listener stats, chart rankings, contacts and more on the Pop Health Podcast podcast page.